TABLE 2.
Cox multivariate analysis of overall survival of all patients (n = 128)
| Variables | Log‐rank test | Multivariate analysis | ||
|---|---|---|---|---|
| HR | 95% CI | p‐Value | ||
| Sex (male vs. female) | 0.850 | |||
| Age (≥65 y vs. <65 y) | 0.037 | |||
| Smoking history (yes vs. no) | 0.160 | 2.025 | 1.057–3.881 | 0.034 |
| Adenocarcinoma (yes vs. no) | 0.449 | |||
| Stage at diagnosis (IV vs. III) | 0.169 | |||
| Number of distant metastases (≥4 vs. <4) | 0.818 | |||
| Bone metastasis (yes vs. no) | 0.019 | 1.994 | 1.171–3.394 | 0.011 |
| Brain metastasis (yes vs. no) | 0.214 | |||
| Liver metastasis (yes vs. no) | 0.910 | |||
| Adrenal gland metastasis (yes vs. no) | 0.093 | |||
| ALK‐TKI as first‐line therapy (yes vs. no) | 0.090 | |||
| Received second‐generation ALK‐TKI (yes vs. no) | 0.003 | 0.691 | 0.369–0.992 | 0.021 |
| Received third‐generation ALK‐TKI (yes vs. no) | <0.001 | 0.250 | 0.115–0.547 | 0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; p‐values <0.05 were statistically significant; ALK‐ TKI, anaplastic lymphoma kinase‐tyrosine kinase inhibitor.